{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:28:28Z","timestamp":1761895708485},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2013,8,17]],"date-time":"2013-08-17T00:00:00Z","timestamp":1376697600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s10067-013-2361-9","type":"journal-article","created":{"date-parts":[[2013,8,16]],"date-time":"2013-08-16T02:00:39Z","timestamp":1376618439000},"page":"1819-1822","source":"Crossref","is-referenced-by-count":20,"title":["A case of infliximab-induced lupus in a patient with ankylosing spondylitis: is it safe switch to another anti-TNF-\u03b1 agent?"],"prefix":"10.1007","volume":"32","author":[{"given":"T\u00e2nia","family":"Santiago","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana Galante","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o","family":"Rovisco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e1tia","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando","family":"Malcata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Ant\u00f3nio Pereira","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,8,17]]},"reference":[{"key":"2361_CR1","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/rheumatology\/kep080","volume":"48","author":"EL Williams","year":"2009","unstructured":"Williams EL, Gadola S, Edwards CJ (2009) Anti-TNF-induced lupus. Rheumatology (Oxford) 48:716\u2013720","journal-title":"Rheumatology (Oxford)"},{"key":"2361_CR2","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1191\/0961203305lu2240rr","volume":"14","author":"L Rycke De","year":"2005","unstructured":"De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F (2005) The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus 14:931\u2013937","journal-title":"Lupus"},{"key":"2361_CR3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s10067-002-0654-5","volume":"22","author":"M Bandt De","year":"2003","unstructured":"De Bandt M, Vittecoq O, Descamps V, Le Loet X, Meyer O (2003) Anti-TNF alpha-induced systemic lupus erythematosus. Clin Rheumatol 22:56\u201361","journal-title":"Clin Rheumatol"},{"key":"2361_CR4","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.autrev.2009.10.003","volume":"9","author":"M Ramos-Casals","year":"2010","unstructured":"Ramos-Casals M, Alvarez R-P, Diaz-Lagares C, Cuadrado M-J, Khamashta MA, BIOGEAS Study Group (2010) Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 9:188\u2013193","journal-title":"Autoimmun Rev"},{"key":"2361_CR5","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/rheumatology\/kei220","volume":"45","author":"C Perez-Garcia","year":"2006","unstructured":"Perez-Garcia C et al (2006) Drug-induced systemic lupus erythematous in ankylosing spondylitis associated in infliximab. Rheumatology 45:114\u2013116","journal-title":"Rheumatology"},{"key":"2361_CR6","author":"O Akg\u00fcl","year":"2012","unstructured":"Akg\u00fcl O, K\u0131l\u0131\u00e7 G, K\u0131l\u0131\u00e7 E, C\u00fcce I, Ozg\u00f6\u00e7men SA (2012) Patient with ankylosing spondylitis who developed infliximab-induced lupus and treated with etanercept. Rheumatol Int. doi: 10.1007\/s00296-012-2617-8","journal-title":"Rheumatol Int"},{"key":"2361_CR7","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00296-008-0684-7","volume":"29","author":"H Bodur","year":"2009","unstructured":"Bodur H, Eser F, Konca S, Arikan S (2009) Infliximab-induced lupus-like syndrome in a patient with ankylosing spondylitis. Rheumatol Int 29:451\u2013454","journal-title":"Rheumatol Int"},{"key":"2361_CR8","first-page":"1116","volume":"26","author":"A Mounach","year":"2008","unstructured":"Mounach A, Ghazi M, Nouijai A, Ghozlani I, Achemlal L, Bezza A, El Maghraoui A (2008) Drug-induced lupus-like syndrome in ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 26:1116\u20131118","journal-title":"Clin Exp Rheumatol"},{"key":"2361_CR9","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-4632.2011.04871.x","volume":"50","author":"VL Williams","year":"2011","unstructured":"Williams VL, Cohen PR (2011) TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol 50:619\u2013625","journal-title":"Int J Dermatol"},{"key":"2361_CR10","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3899\/jrheum.100830","volume":"38","author":"C Ye","year":"2011","unstructured":"Ye C, Sholter D, Martin L, Keeling S (2011) Successful switch of patients with rheumatoid arthritis developing anti-tumor necrosis factor (anti-TNF)-induced lupus to another anti-TNF agent. J Rheumatol 38:1216","journal-title":"J Rheumatol"},{"key":"2361_CR11","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0025-6196(11)60668-X","volume":"84","author":"DA Wetter","year":"2009","unstructured":"Wetter DA, Davis MD (2009) Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc 84:979\u2013984","journal-title":"Mayo Clin Proc"},{"key":"2361_CR12","first-page":"S141","volume":"22","author":"JJ Cush","year":"2004","unstructured":"Cush JJ (2004) Unusual toxicities with TNF inhibition: heart failure and drug-induced lupus. Clin Exp Rheumatol 22:S141\u2013S147","journal-title":"Clin Exp Rheumatol"},{"key":"2361_CR13","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/0961203308093922","volume":"18","author":"L Kocharla","year":"2009","unstructured":"Kocharla L, Mongey AB (2009) Is the development of drug-related lupus a contraindication for switching from one TNF alpha inhibitor to another? Lupus 18:169\u20137","journal-title":"Lupus"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-013-2361-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-013-2361-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-013-2361-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T04:57:28Z","timestamp":1559105848000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-013-2361-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,17]]},"references-count":13,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["2361"],"URL":"https:\/\/doi.org\/10.1007\/s10067-013-2361-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,17]]}}}